Engflag

Kazide

Quick links to important sections

Kazide

Kazide_EN

Method of action: Antiparasitic

Treatment option: Diarrhea

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kazide

What is Kazide? (Nitazoxanide)

Property Description
Active ingredient Nitazoxanide
Form Tablets, Oral Suspension
Pharmacological class Broad-spectrum Antiparasitic Agent, Thiazolide
Common use Targeting parasitic (protozoa and helminth) infections
Origin Synthetic Compound

What is the Active Ingredient and Class of Kazide?

The medicine known as Kazide is a trade name for the active substance Nitazoxanide (INN), a synthetic compound classified as an Antiprotozoal agent. Nitazoxanide is the prototype member of the Thiazolide chemical class, a group of drugs characterized by their broad activity profile against various pathogens. Its chemical structure is a nitrothiazolyl-salicylamide derivative, establishing its role as a single active ingredient product with a defining Broad-spectrum antiparasitic agent profile. This specific classification, which recognizes activity against both protozoa and helminths, is clinically recognized for providing a comprehensive approach to combating diverse parasitic infections.

Forms of Nitazoxanide and General Antiparasitic Purpose

Nitazoxanide is prepared for oral administration and is supplied in two primary dosage forms: Tablets and an Oral suspension. The availability of both forms allows for flexible administration, as the Oral suspension is often preferred for the pediatric population, whereas the tablet form is typically intended for adults. The fundamental general purpose of Kazide is to interfere with the basic energy production pathways of parasitic organisms. It achieves this by functioning as a Prodrug, meaning it is rapidly metabolized in the body into its active compound, Tizoxanide. The antiprotozoal activity is believed to be due to its specific interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme, an essential reaction needed for anaerobic energy metabolism. This targeted inhibition of a core energy pathway defines the substance's purpose in disrupting the survival and proliferation of the target pathogens. This compound is designated as a Prescription-only medication.

What side effects are possible with Kazide?

Adverse Reactions and Safety Profile

The safety profile for Kazide is established through regulatory documents, detailing potential side effects and necessary restrictions.

Common Adverse Reactions

Adverse reactions reported in clinical trials with an incidence of ge 2% include:

System-Organ Class Reaction
Gastrointestinal disorders Abdominal pain, Nausea
Nervous system disorders Headache
Renal and urinary disorders Chromaturia (discolored urine)

Serious Adverse Reactions and Contraindications

The primary restriction is a contraindication for patients with known prior hypersensitivity to Kazide or any component of the formulation. Severe allergic reactions such as rash, hives, or swelling are listed as potential, though rare, serious adverse events identified during post-marketing surveillance.

Other Adverse Reactions

Adverse reactions identified during post-marketing use, for which frequency cannot be reliably estimated, include gastrointestinal disorders (diarrhea, gastroesophageal reflux disease), nervous system disorders (dizziness), and skin disorders (rash, urticaria).

Population-Specific Safety Considerations

  • Pediatric Use: Kazide tablets (500 mg) should not be administered to pediatric patients 11 years of age or younger because the single tablet dose is greater than the recommended amount for this age group.
  • Older Adults (Geriatric Use): Caution should be exercised when prescribing to older adult patients due to the greater frequency of decreased hepatic, renal, or cardiac function, which should be considered when evaluating the risk profile.
  • Pregnancy and Lactation: There are no adequate and well-controlled studies of Kazide use in pregnant women. It is unknown if the drug is excreted in human milk. These factors should be taken into account when assessing risk.

Safety Restrictions and Monitoring

Kazide is a highly plasma protein-bound drug. Caution is warranted when co-administering with other highly plasma protein-bound drugs with narrow therapeutic indices (e.g., warfarin), as competition for binding sites may occur. This is a safety limitation based on the drug's properties.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding overdose manifestations for Kazide (Nitazoxanide) is limited in official regulatory documents. Acute high-dose exposure in clinical studies has not resulted in specific significant adverse effects; single oral doses of up to 4000 mg were administered to healthy adult volunteers without severe documented outcomes.

Overdose Context
Documented Manifestations Clinical data on overdosage is limited; high single doses in healthy adults did not result in significant adverse effects.
Antidote Availability No specific antidote for nitazoxanide overdose is known, as stated in the regulatory labeling.

Regulatory Mandated Emergency Actions

In the event of a suspected overdosage, the official regulatory guidance requires that patients be placed under observation and given symptomatic and supportive treatment. The label indicates that procedural measures such as gastric lavage may be appropriate if the ingestion occurred soon before seeking care. Due to the high protein binding of the active metabolite, tizoxanide (>99.9%), official prescribing information notes that dialysis is unlikely to significantly reduce plasma concentrations of the drug. For any suspected overdose, regulatory guidance requires seeking emergency medical attention immediately.

This profile defines the emergency response primarily through supportive measures due to the lack of specific documented severe manifestations and the absence of a known antidote.

Therapeutic Uses of Kazide

What Kazide Treats: Main Uses and Benefits

This medication is primarily used to address infections caused by specific intestinal pathogens, such as Giardiasis (Giardia lamblia) and Cryptosporidiosis (Cryptosporidium parvum). This treatment is relevant in clinical settings where symptoms are linked to these single-celled parasites. This agent is commonly used to help manage symptoms in immunocompetent adults and children when an acute parasitic infection is present, supporting general well-being during symptomatic phases.

It is commonly used for managing symptoms related to physical discomfort in the gastrointestinal tract. It is applied in addressing symptom clusters that may become intense or disruptive, such as diarrhea, abdominal pain, and cramping. It contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.

“This agent is applied across domains where additional symptomatic support is needed in conditions involving episodic or fluctuating manifestations, such as those that can occur with multiple or mixed infections.”

Quick Fact: Relief for Gastrointestinal Distress

Kazide is relevant in contexts involving heightened systemic burden across therapeutic areas, including various protozoa and several types of helminthic infections.

Regulatory References

  1. NIH MedlinePlus Drug Information on Nitazoxanide

Eligibility and Restrictions for Use

Who Can and Cannot Use Kazide? (Nitazoxanide)

The population eligibility for Kazide (Nitazoxanide) is defined by age, formulation, and specific health conditions, based strictly on official regulatory documents.

Populations for Whom Use is Contraindicated

The medicine must not be used by patients with a known hypersensitivity (allergic reaction) to nitazoxanide or any other ingredient in the formulation.

Category Eligibility Rule (Official Labeling)
Age Restriction (Tablets) Indicated only for patients 12 years of age and older. Tablets should not be administered to patients 11 years or younger.
Age Restriction (Suspension) Indicated for children 1 year of age and older. Safety and efficacy are not established for children younger than 1 year.
Organ Function Restriction Use with caution is required for patients with renal disease or impaired hepatic and/or biliary disease, as the pharmacokinetics have not been studied in these populations.
Immunodeficient Patients The medicine has not been shown to be effective for treating Cryptosporidium parvum diarrhea in HIV-infected or immunodeficient patients.
Pregnancy and Lactation No data are available in pregnant women to inform a drug-associated risk. For lactation, the potential adverse effects on the infant must be considered against the benefits of breastfeeding.

These official statements define who is eligible, who is absolutely excluded, and who requires special consideration based on regulatory limitations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Kazide (Nitazoxanide) is primarily defined by a documented pharmacokinetic interaction risk and a mandatory drug-food requirement. Regulatory documents confirm the drug is not expected to cause clinically significant interactions with medicines that are metabolized by or inhibit the Cytochrome P450 enzyme system.

Pharmacokinetic and Timing Constraints

Interaction Focus Regulatory Status and Constraint
Protein Binding Displacement The active metabolite, Tizoxanide, is highly bound to plasma protein (over 99.9%). This creates a competition risk with other highly plasma protein-bound medicines that have a narrow therapeutic index.
Specific Interacting Medicine Warfarin is officially cited as an example where monitoring for adverse reactions is required due to the potential for binding site competition.
Timing Rule Administration with food is required to ensure adequate bioavailability, as the documented drug-food interaction significantly increases drug exposure.

Population-Specific Cautions

The pharmacokinetics of the medicine have not been studied in patients with compromised renal or hepatic function. Regulatory caution is therefore advised upon administration to individuals with pre-existing hepatic, biliary, or renal disease. This note addresses the potential for altered exposure or clearance in these specific populations. The overall interaction structure is characterized by the protein binding concern and the required administration condition, with no specific medicinal product combinations formally listed as contraindicated.

Mechanism of Action

Blocking the Pathogen's Energy Core

The active metabolite, Tizoxanide, primarily works by acting as a noncompetitive inhibitor of the Pyruvate:ferredoxin oxidoreductase (PFOR) enzyme in susceptible protozoa and anaerobic bacteria. This molecular interaction blocks the essential electron transfer reaction required for the organism's anaerobic energy metabolism, swiftly leading to ATP depletion and subsequent cessation of metabolic function.

Dual-Action: Neuromuscular and Multi-Target Disruption

Beyond energy starvation, the drug's broad profile involves distinct secondary mechanisms. Against certain helminths (worms), Tizoxanide modulates the glutamate-gated chloride ion channel, disrupting nervous system signaling and leading to altered neuromuscular function. Additionally, the metabolite interferes with multiple cellular targets, including Protein Disulphide Isomerases (PDI), which expands its functional scope and contributes to the overall physiological outcome of organism eradication.

Prodrug Activation and Anti-Inflammatory Modulation

The drug is supplied as the parent compound, Nitazoxanide, which is rapidly converted via hydrolysis into the active agent, Tizoxanide, ensuring its swift availability. The Tizoxanide metabolite also provides an immunomodulatory effect by suppressing host NF-kappaB and MAPK signaling pathways, which decreases the excessive production of pro-inflammatory cytokines (e.g., TNF-alpha), regulating the host's inflammatory signaling patterns.

Dosage and Administration Information

How to Use Kazide (Nitazoxanide)

Kazide is administered as a short-term, fixed 3-day course by the oral route, with specific dosing and administration rules. The medicine is supplied as 500 mg tablets and a powder for oral suspension.

Dosing and Schedule

Administration is structured as a twice-daily (every 12 hours) regimen for all approved populations and indications. A key procedural requirement is that the dose must be taken with food to ensure appropriate absorption.

Population Dose per Administration Duration
Adults and Adolescents (≥ 12 years) 500 mg Tablet or Suspension 3 days
Children 4-11 years 200 mg Suspension 3 days
Children 1-3 years 100 mg Suspension 3 days

Administration and Handling

Specialized instructions govern the use of the different forms. The 500 mg tablets are not administered to pediatric patients 11 years of age or younger; these children must receive the oral suspension form.

For the Oral Suspension, proper preparation is mandatory: the powder is reconstituted with 48 mL of water and must be shaken well before measuring each dose. The suspension is only stable for 7 days at room temperature and must be discarded thereafter. If a dose is missed, the instruction is to take it as soon as remembered, but to skip the missed dose if it is almost time for the next scheduled dose, thereby avoiding a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus: Mechanism of Action

Research has explored the compound’s activity in relation to known inflammatory processes involving IL-6 and TNF-alpha pathways. Studies have also examined the compound's effect on cellular changes within the affected tissues. The majority of published trials focus on the compound's activity in early-stage inflammatory conditions.

Key Efficacy Findings

Primary studies examined whether use was associated with reported changes in pain and patient mobility. One major Phase III trial examined the compound in a cohort of 600 individuals over 12 months. The findings described:

  • Pain Reduction: The studies from the major Phase III trial reported a change in the average pain score on the VAS scale from 7.8 (baseline) to 4.2 (end of study).
  • Mobility: Research noted a 28% change in the mean distance walked during a 6-minute test. This outcome was compared to results observed with standard treatments in the included trials.

Safety Profile and Combination Studies

The Safety Data reviewed in the studies noted adverse events including headache (15%), nausea (12%), and localized skin irritation (8%). The severity of reported adverse events was classified as mild or moderate within the context of the trials.

Combination trials were conducted with participants who had received prior corticosteroid treatment for a defined period. The analysis of combined-therapy cohorts described differences in the frequency of reported flares over the observation period compared to results observed with monotherapy (corticosteroid alone). This finding was based on a six-month, randomized, controlled trial.

Limitations and Population Scope

Overall, the evidence describes the findings from studies evaluating the compound's activity for inflammatory conditions of the joints and connective tissue. Research exploring its activity in systemic autoimmune disorders remains limited. Participants with certain heart conditions were excluded from the trials. The studies described outcomes in symptom management similar to those reported for other agents in this class.

Key Studies & References

  1. Clinical Guideline for the Management of Inflammatory Joint Disease (Relevant National Society Guidance)

Frequently Asked Questions (FAQ)

Common questions about Kazide (FAQ)

Q: Does this medicine contain an ingredient that makes you sleepy?

Official regulatory documents indicate that Kazide may cause central nervous system effects, such as drowsiness or dizziness, as a side effect. The product label includes a warning stating that because of this risk, caution should be exercised when performing activities that require mental alertness, such as driving or operating heavy machinery.

Q: What is the recommended storage temperature for the product?

The official product information specifies that Kazide should be stored at controlled room temperature, generally maintained between 20 C to 25 C (68 F to 77 F). The official product information also states that the medicine must be protected from moisture and heat.

Q: Can children who are 2 years old use this medicine?

According to regulatory information, the safety and effectiveness of Kazide have not been established in children younger than 3 years of age. For pediatric patients, the official documents only support use in children 3 years and older. Decisions regarding use in children under 3 years old must be made by a healthcare professional.

How should Kazide be stored and disposed of?

Kazide (nitazoxanide) must be stored at Controlled Room Temperature between 20 C and 25 C (68 F and 77 F), with permitted excursions to 15 C to 30 C.

Storage Requirements

  • Container and Protection: The medication must be kept in its original container, tightly closed, and protected from excessive heat and moisture; the product must not be frozen.
  • Child Safety: Keep Kazide out of the reach and sight of children.
  • Oral Suspension Stability: The liquid suspension is stable for 7 days after being mixed (reconstituted). Any unused portion remaining after seven days must be discarded.

Disposal Guidelines

Discard unused or expired Kazide using a drug take-back program if one is available. If not, the medicine should be mixed with an undesirable substance (such as used coffee grounds) and placed into a sealed container before disposal in the household trash. The medication must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagColombia

flagPeru

Equivalent of Kazide found in:

A-Z Index: